Newsroom

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een mondiaal oncologiebedrijf, heeft vandaag nieuwe overlevingsresultaten bekendgemaakt uit de geplande tweede tussentijdse analyse (IA2) en de definitieve formele analyse van de Fase 3-studie HERIZON-GEA-01. Deze resultaten bevestigen opnieuw het voordeel van TEVIMBRA ® (tislelizumab) in combinatie met ZIIHERA® (zanidatamab) en chemotherapie als eerstelijnsbehandeling voor patiënten met HER2-posi...

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute neue Überlebensdaten aus der geplanten zweiten Zwischenanalyse (IA2) und der abschließenden formellen Analyse der Phase-3-Studie HERIZON-GEA-01-bekannt, die den Nutzen von TEVIMBRA® (Tislelizumab) in Kombination mit ZIIHERA® (Zanidatamab) und einer Chemotherapie als Erstlinienbehandlung für Patienten mit HER2-positivem, lokal fortgeschritte...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda oncologica globale, oggi ha annunciato nuovi risultati di sopravvivenza della seconda analisi ad interim (IA2) e un'analisi finale formale dello studio clinico di Fase 3 HERIZON-GEA-01, confermando ulteriormente il beneficio di TEVIMBRA® (tislelizumab) più ZIIHERA® (zanidatamab) e chemioterapia come trattamento di prima linea per i pazienti affetti da adenocarcinoma gastroesofageo (GEA) HE...

NEW YORK--(BUSINESS WIRE)--The Wella Company, das weltgrößte Unternehmen, das ausschließlich Produkte für Haare und Nägel vertreibt, gab heute strategische Veränderungen in der Führungsspitze bekannt, um die nächste Phase des Unternehmens zu unterstützen, in der auch eine neue Organisationsstruktur für den Bereich Global Brand and Marketing vorgesehen ist. The Wella Company gliedert ihren Bereich Global Brand and Marketing künftig in zwei eigenständige, sich jedoch ergänzende Teams, die jeweils...

MIAMI & SEOUL, South Korea--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit’s AI-powered pathology platform, for tumor microenvironment analysis in support of Summit’s immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment featur...

SAN FRANCISCO--(BUSINESS WIRE)--AWKO Law LLP is investigating a data breach that led to unauthorized access to the sensitive information of patients of Quest Diagnostics, a New Jersey-based diagnostic testing company. Quest Diagnostics disclosed in its Securities and Exchange Commission (“SEC”) Form 8-K filing that on October 21, 2026, it identified unauthorized activity in its Quanum Lab Services Manager, a platform where certain clients can place test orders and receive or look up their resul...

LAKE MARY, Flórida e POOLER, Geórgia--(BUSINESS WIRE)--A Mitsubishi Power Americas, Inc. anunciou hoje planos para expandir suas instalações da Savannah Machinery Works, um importante centro de fabricação e serviços nos EUA para turbinas a gás de classe avançada, turbinas a vapor e equipamentos de geração de energia, atendendo a clientes em todas as Américas. A expansão das instalações irá acelerar a capacidade da Mitsubishi Power de atender às necessidades sem precedentes de geração de energia...

LAKE MARY, Florida, y POOLER, Georgia--(BUSINESS WIRE)--Mitsubishi Power Americas, Inc. anunció el día de hoy sus planes para ampliar sus instalaciones de Savannah Machinery Works, un centro clave de fabricación y servicio en Estados Unidos para turbinas de gas de clase avanzada, turbinas de vapor y equipos de generación de energía que atienden a clientes en todo el continente americano. Las instalaciones ampliadas acelerarán la capacidad de Mitsubishi Power para satisfacer necesidades de gener...

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller is investigating potential violations of U.S. federal securities laws involving ServiceTitan, Inc....

BRENTWOOD, Tenn.--(BUSINESS WIRE)--Delek Logistics Partners, LP (NYSE: DKL) (“Delek Logistics”) today declared its quarterly cash distribution for the third quarter 2026 of $1.14 per common limited partner unit, or $4.56 per common limited partner unit on an annualized basis. The third quarter 2026 cash distribution is payable on November 10, 2026, to unitholders of record on November 3, 2026. About Delek Logistics Partners, LP Delek Logistics is a midstream energy master limited partnership he...